The Conversation (0)
Knight Therapeutics reported its financial results for the third quarter of 2017.
Knight Therapeutics (TSX:GUD) reported its financial results for the third quarter of 2017.
As quoted in the press release:
“This past quarter our team was focused on advancing our product pipeline and evaluating opportunities to build our portfolio of innovative pharmaceuticals,” said Jonathan Ross Goodman, CEO of Knight. “In the quarters ahead, we will look to capitalize on GUD opportunities for growth.”
As at September 30, 2017, Knight had over $760,000 in cash, cash equivalents and marketable securities and 142,772,805 common shares outstanding. From this strong cash position, Knight will continue to pursue business and corporate development opportunities.
Click here to read the full press release.
Source: www.marketwired.com
